Urocidin, also known as MCNA (Mycobacterium phlei Cell Wall-nucleic acid complex) is filed at FDA for treatment of Bladder Cancer- Telesta Therapeutics
Telesta Therapeutics Inc. has announced that it has submitted a Biologics License Application (BLA) to the FDA for Urocidin, also known as MCNA (Mycobacterium phlei Cell Wall-nucleic acid complex). MCNA is Telesta’s novel biologic immunotherapy for the treatment of high-risk non-muscle-invasive bladder cancer patients who have failed first-line BCG therapy.
Telesta’s BLA submission has been made following extensive and ongoing dialogue with the FDA, including a formal pre-BLA meeting in November 2014 and a Type C facility meeting in February 2015.
Telesta Therapeutics was formerly Bioniche Life Sciences.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.